Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on innovative aesthetic and therapeutic solutions. Founded in 2011, Revance has made significant strides in the industry, particularly with its proprietary DaxibotulinumtoxinA injection, which offers a unique, long-lasting alternative to traditional neuromodulators.
With a strong presence in the aesthetic and therapeutic sectors, Revance is committed to advancing patient care through its cutting-edge products. The company has achieved notable milestones, including successful clinical trials and regulatory approvals, positioning itself as a key player in the competitive landscape of biotechnology. Revance's dedication to innovation and quality sets it apart, making it a trusted name in the field.
-20 vs industry average
Revance Therapeutics, Inc.’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Revance Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Revance Therapeutics, Inc. yet.
Revance Therapeutics, Inc.'s reported carbon emissions
Revance Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reduce greenhouse gas emissions at this time.
As a current subsidiary, Revance's climate initiatives and emissions data may be influenced by its corporate family structure. However, no specific cascading data from parent organisations or related entities has been provided. This indicates that Revance Therapeutics, Inc. is still in the early stages of developing its climate strategy and emissions reporting.
In the broader context of the biotechnology industry, companies are increasingly recognising the importance of sustainability and climate commitments. Revance may need to align with industry standards and expectations to enhance its environmental performance and transparency in the future.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Revance Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Revance Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Revance Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project